Other articles

ticagrelor vs. aspirina

Empagliflozin: Better Quality of Life for Patients with Cardiac Failure and Preserved Ejection Fraction

Empagliflozin: Better Quality of Life for Patients with Cardiac Failure and Preserved Ejection Fraction

Empagliflozin has shown early and sustained improved quality of life (at least for a year) in patients with cardiac failure and preserved function. Patients with cardiac failure and preserved ejection fraction present a deteriorated quality of life. The EMPEROR-Preserved assessed the efficacy of Empagliflozin in several baseline health status assessments. HRQoL was measured using the

Dieta proinflamatoria y su potencial para desencadenar eventos cardiovasculares

Dietary Guidelines to Improve Cardiovascular Health in 2021

A poor diet is associated with high risk of heart disease, morbidity and mortality.  This scientific document emphasizes the importance of a dietary pattern beyond food or nutrients: it highlights the critical role of early nutrition, presents us with elements to build healthy eating habits and underscores the need to introduce structural changes to achieve

Estenosis aórtica moderada y disfunción ventricular ¿debería apurarse la indicación del recambio?

Swan Ganz Associated with Better Outcomes in Cardiogenic Shock: Is It Back?

The Swan Ganz catheter has been used in the clinical practice for years. However, its usefulness remains under discussion and its use keeps dropping.   A new analysis published in JAHA might bring it back at least in the context of cardiogenic shock, where it showed improved prognosis and more effective complexity management.  Recently, the lack

AHA 2021 | CRAVE: Seguridad del café para los trastornos del ritmo

AHA 2021 | CRAVE: Coffee Safety in Rhythm Disorders

On the one side, caffeine can increase arrythmias or interfere with sleeping, but on the other hand, it helps people feel more energetic and do more physical activity.  These data contribute to the evidence supporting the fact that people who present, or are at risk of presenting supra ventricular arrythmias or atrial fibrillation might not

hipertensión refractaria

Hypertensive Patients: Maximizing Doses or Adding New Drugs

Adding new medication in moderate doses to control hypertension conveniently maximizes efficacy, reduces adverse effects and minimizes costs, among other advantages.  On the flipside, patients having to remember a whole list of drugs and their combination will often lead to non-adherence or forgetfulness. The latter has been shown not only by dedicated trials, but also

ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate

The results of the STEP study were presented at the European Society of Cardiology (ESC) 2021 Congress! The main finding from this research was that an ideal target of 110 mmHg or at least <130 mmHg blood pressure (compared with a target of 130 mmHg or at least 150 mmHg) yielded an absolute risk reduction of composite events of

ESC 2021 | GREENNESS: Sorpresivo nuevo factor protector contra la enfermedad cardiovascular

ESC 2021 | GREENNESS: Surprising New Protective Factor against Cardiovascular Disease

What Is “Greenness”? This factor—which generally refers to the proximity to vegetation, as measured by satellite pictures—could serve as a new protection against cardiovascular disease. During five years (the total research time), this study compared individuals who lived in the lowest tercile of “greenness” with those who lived in the highest tercile (i.e., those who

ESC 2021 | Empagliflozina en insuficiencia cardíaca con función deteriorada y preservada

ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction

The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death or hospitalization for heart failure (HF) in both patients with reduced and with preserved function. The primary endpoint (a composite of death and hospitalization for HF) was reduced by 21% on a relative basis with sodium/glucose cotransporter 2

Pacientes que no siguen nuestro consejo y sorpresivamente tienen menos eventos

Polypharmacy in Older Adults Elderly: What Medication to Discontinue

Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead to multiple problems; in addition, over time, cognitive deterioration will make complicated drug management schemes even more difficult for patients to handle.  Aware of this problem, physicians often try to simplify schemes by discontinuing drugs, but what should

ACC 2021 | Revive la denervación renal de la mano del RADIANCE-HTN TRIO

ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to this new study presented at ACC 2021 simultaneously published in the Lancet. Renal denervation reduces ambulatory daily systolic blood pressure by 8 mmHg vs 3 mmHg in the sham procedure branch.  This translates into a mean 4.5 mmHg

ACC 2021 | Sacubitril/valsartan no es superior al ramipril luego de un IAM

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in patients compared against ramipril. These data were provided by the PARADISE-MI presented today during the scientific sessions at ACC 2021. The combination sacubitril/valsartan had gathered prior evidence (basically from the PARADIGM-HF) for its superiority in terms of total

Top